Health & Fitness
Health and Fitness
Health and Fitness
Wed, June 30, 2010
Tue, June 29, 2010 
CHICAGO--([ BUSINESS WIRE ])--Zacks.com Analyst Blog features: Bristol-Myers Squibb Co. (NYSE: [ BMY ]), AstraZeneca Plc (NYSE: [ AZN ]), Merck (NYSE: [ MRK ]), Amylin (Nasdaq: [ AMLN ]) and Sanofi (NYSE: [ SNY ]).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: [ http://at.zacks.com/?id=4579 ]
Here are highlights from Mondaya™s Analyst Blog:
BMY Presents Positive Data
Recently, Bristol-Myers Squibb Co. (NYSE: [ BMY ]) reported encouraging results from a late-stage study evaluating the combination therapy of Onglyza (saxagliptin) and metformin in patients suffering from type II diabetes. Onglyza has been co-developed by Bristol-Myers and AstraZeneca Plc (NYSE: [ AZN ]). The data were presented at the 70th American Diabetes Association Annual Scientific Sessions.
The results from the multicenter, randomized, double-blind, active-controlled study revealed that the combination therapy led to long-term glycemic improvement in previously untreated patients suffering from type II diabetes. Glycemic control refers to the levels of blood sugar (glucose) in a person suffering from diabetes. The disease was unsatisfactorily controlled by diet and exercise compared with a 10 mg dose of saxagliptin or metformin alone.
Onglyza is under review in more than 58 countries across the globe. The drug has already been approved in 43 countries including the United States , Canada , Mexico , 30 European Union nations, Chile , India , Brazil, Argentina and Switzerland . In 2009, the U.S. Food and Drug Administration (FDA) approved Onglyza as an addition to diet and exercise to improve blood sugar (glycemic) control in adults suffering from type II diabetes.
Encouraging Data on dapagliflozin Bristol presented encouraging data on another of its type II diabetes candidates, dapagliflozin. Data from the 24-week late-stage study (n=800) revealed that type II diabetes patients treated with dapagliflozin underwent a significant reduction in their blood sugar levels. Dapagliflozin was being assessed as an add-on therapy to insulin in type II diabetes patients (aged between 18-80 yrs) whose disease was inadequately controlled by insulin.
Furthermore, data from the randomized, double-blind, placebo-controlled study revealed that dapagliflozin caused statistically significant weight loss and a slight reduction in the needed insulin dose. Dapagliflozin is being co-developed with AstraZeneca.
Lucrative Type II diabetes market
The type II diabetes market is highly lucrative with a huge unmet need. According to data released by GlobalData, the type II diabetes market was worth $21.9 billion in 2009 across the globe. This represented a compound annual growth rate of 11.2% between 2001 and 2009. The prevalence of diabetes in the US and major European countries is on the rise. The market is highly competitive and has players like Mercka™s (NYSE: [ MRK ]) Januvia, Amylina™s (Nasdaq: [ AMLN ]) Byetta and Sanofia™s (NYSE: [ SNY ]) Lantus.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: [ http://at.zacks.com/?id=5514 ].
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: [ http://at.zacks.com/?id=5516 ]
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at [ http://at.zacks.com/?id=4580 ].
Visit [ http://www.zacks.com/performance ] for information about the performance numbers displayed in this press release.
Follow us on Twitter: [ http://twitter.com/zacksresearch ]
Join us on Facebook: [ http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts ]
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
